<code id='FC32912701'></code><style id='FC32912701'></style>
    • <acronym id='FC32912701'></acronym>
      <center id='FC32912701'><center id='FC32912701'><tfoot id='FC32912701'></tfoot></center><abbr id='FC32912701'><dir id='FC32912701'><tfoot id='FC32912701'></tfoot><noframes id='FC32912701'>

    • <optgroup id='FC32912701'><strike id='FC32912701'><sup id='FC32912701'></sup></strike><code id='FC32912701'></code></optgroup>
        1. <b id='FC32912701'><label id='FC32912701'><select id='FC32912701'><dt id='FC32912701'><span id='FC32912701'></span></dt></select></label></b><u id='FC32912701'></u>
          <i id='FC32912701'><strike id='FC32912701'><tt id='FC32912701'><pre id='FC32912701'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:knowledge    - browse:9
          Adam's take main illustration
          Molly Ferguson/STAT

          Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

          A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

          advertisement

          With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus